Sprint Bioscience ABOSTO:SPRINT -2.06%32 Net Current Asset Value is kr0.97 as of Mar. 2026, which is 100% below its 10-year median of 7.48. GuruFocus rates OSTO:SPRINT with a GF Score™ of 32/100 and a GF Value™ of kr2.18 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 942 Biotechnology companies, Sprint Bioscience AB ranks better than 56.9% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Sprint Bioscience AB's net current asset value per share for the quarter that ended in Mar. 2026 was kr0.97.
The historical rank and industry rank for Sprint Bioscience AB's Net Current Asset Value or its related term are showing as below:
OSTO:SPRINT'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.35 Med: 7.48 Max: 79.17
Current: 3.92
During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of Sprint Bioscience AB was 79.17. The lowest was 1.35. And the median was 7.48.
OSTO:SPRINT's Price-to-Net-Current-Asset-Value is ranked better than 56.9% of 942
companies
in the Biotechnology industry
Industry Median: 4.875
vs OSTO:SPRINT: 3.92
Sprint Bioscience AB (OSTO:SPRINT) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Sprint Bioscience AB Net Current Asset Value Related Terms
Sprint Bioscience AB Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for Sprint Bioscience AB's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sprint Bioscience AB Net Current Asset Value Chart
OSTO:SPRINT vs VRTX, REGN, ALNY: Net Current Asset Value Comparison
For the Biotechnology subindustry, Sprint Bioscience AB's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sprint Bioscience AB Price-to-Net-Current-Asset-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sprint Bioscience AB's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Sprint Bioscience AB's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of kr0.97 mean?
Sprint Bioscience AB (OSTO:SPRINT) has a Net Current Asset Value of kr0.97 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Sprint Bioscience AB and its competitors. This is 87% below median its historical median of 7.48. Over the past decade, Sprint Bioscience AB's Net Current Asset Value has ranged from 1.35 to 79.17. According to the industry distribution chart, Sprint Bioscience AB ranks #406 out of 942 companies in the Biotechnology industry, placing it in the top 43.1%.
Is Sprint Bioscience AB's Net Current Asset Value too high?
Sprint Bioscience AB's current Net Current Asset Value of kr0.97 is 87% below median its 10-year median of 7.48. Over the past 10 years, this metric has ranged from a low of 1.35 to a high of 79.17. Based on the distribution chart, Sprint Bioscience AB ranks #406 out of 942 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Sprint Bioscience AB has a GF Score™ of 32/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sprint Bioscience AB's Net Current Asset Value compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sprint Bioscience AB ranks #406 out of 942 companies for Net Current Asset Value. This puts Sprint Bioscience AB in the upper half of its industry. The industry median Net Current Asset Value is 4.88. Historically, Sprint Bioscience AB's own Net Current Asset Value has ranged from 1.35 to 79.17 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Biotechnology company?
The median Net Current Asset Value among Biotechnology companies is 4.88, based on 942 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Sprint Bioscience AB and its competitors. For the Biotechnology industry, the median Net Current Asset Value is 4.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sprint Bioscience AB's current Net Current Asset Value is kr0.97, which is 87% below median its own 10-year median of 7.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sprint Bioscience AB stock overvalued right now?
Based on GuruFocus' analysis, Sprint Bioscience AB (OSTO:SPRINT) is currently considered Significantly Overvalued. The stock's GF Value™ is kr2.18, compared to a current price of kr3.80 — trading 74.3% above its estimated fair value. The current Net Current Asset Value is kr0.97, which is 87% below median its 10-year median of 7.48. Sprint Bioscience AB's overall GF Score™ is 32/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Sprint Bioscience AB (OSTO:SPRINT), the current Net Current Asset Value is kr0.97 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sprint Bioscience AB (OSTO:SPRINT) Overvalued in 2026?
Based on GuruFocus' analysis, Sprint Bioscience AB stock appears to be overvalued.
The current stock price of kr3.80 is trading 74.3% above its estimated GF Value™ of kr2.18.
GuruFocus considers Sprint Bioscience AB to be Significantly Overvalued.
Key valuation signals for OSTO:SPRINT:
Net Current Asset Value: kr0.97 (87% below median its 10-year median of 7.48)
GF Value™: kr2.18 vs. price of kr3.80 (74.3% above fair value)
No single metric tells the full story. See the OSTO:SPRINT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sprint Bioscience AB is a pharmaceutical company focused on developing drug candidates that can contribute to new treatments for cancer. Its product portfolio includes VRK1, VPS34, PETRA01, TREX1, NNMT, STK25, and DCPS. The company receives revenue for out-licensing drug programs, which include the development of a drug candidate.
32GF Score
Get the complete analysis for OSTO:SPRINT
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:SPRINT has been successfully added to your 
